Sun upbeat on CML molecule that hits T315L mutations
This article was originally published in Scrip
Executive Summary
Sun Pharma Advanced Research Company (SPARC) has outlined details of its emerging NCE pipeline and novel drug delivery system (NDDS) R&D programmes, including an early stage tyrosine kinase inhibitor for chronic myeloid leukaemia (SUN-K706), which inhibits T315I, a key gene mutation that arises during treatment with existing CML marketed drugs.